Member Info for Schlum

Starting to look stronger this afternoon. It will only take a sniff to see this share price move higher.

That is I agree with D Geeman.

My thoughts exactly.

Dowgate capital are no slouches.

Positive review of Optimal will open the door to licensing deals with major pharmas.

No date for publications but it could come at any time.

This webinar has highlighted the extraordinary opportunities for a news pipeline ,that will propel Aptamer the company to much higher levels.

The darkest is before the dawn.

Bye.

True enough.

What do we have, six months/a year to get a deal done?

The risk versus reward in N4P shares is undoubtedly compelling. The potential for 10-20x return in 2025 is there.

AI stocks on both sides of the Atlantic are attracting a lot of investor’s funds. MFAI with its stable of companies , upcoming ipo, and deep discount to NAV, is overlooked ; for now.

N4p , good news required, pronto.

A £5m market cap,is simply way undervaluing a company in joint ventures with mega corporations on breakthrough products.

….it is now moving quickly!

Germanium may just be the catalyst to attract majors to David Price and Rockfire’s door.

Directors setting up their share options, now give us some news.

Wrong board, meant for the MFAI bb.

Re Apta the most positive comment from the CEO of late was his inference that the positive results garnered in the joint work with the US biotech firm , can be a very positive pointer for the AstraZeneca joint project.

Continued steady buying today. The Mkt cap seems very low for a company in the AI field.

AI related companies valuations worldwide are at mega ratings, except on the AIM where they are on the bottom rung.

No news from the company yet on the loan rollover due, nor on the timing of the IPO due in the US.

Announcements re further sales or realisations of investee companies appear overdue.

Discount to NAV remains very large.

The £50 m grant to the N.I. biotech sector via Queen’s University will, if/when confirmed, be a big positive for FAB.

Unsure on that, but that will be two of us who would like to listen in.